Literature DB >> 19097070

A copy number gain of the 6p arm is linked with advanced hepatocellular carcinoma: an array-based comparative genomic hybridization study.

Yasuyo Chochi1, Shigeto Kawauchi, Motonao Nakao, Tomoko Furuya, Kiichiro Hashimoto, Atunori Oga, Masaaki Oka, Kohsuke Sasaki.   

Abstract

In accordance with cancer progression, genomic aberrations accumulate in cancer cells in a stepwise fashion. However, whether there are genomic changes linked with tumour progression remains unclarified. The purpose of this study is to elucidate the relationship between genomic alterations and clinical stages in hepatocellular carcinoma (HCC). A technology of array-based CGH using DNA chips spotted with 1440 BAC clones was applied to 42 surgically removed HCCs to examine the DNA copy number aberrations. A frequent copy number gain was detected on chromosomal regions 1q, 8q and Xq. In particular, gains of 1q42.12, 1q43 and 8q24.3 were detected in more than 65% of tumours. A frequent copy number loss was detected on chromosomal regions 1p, 4q, 6q, 8p and 17p. Losses of 8p21 and 17p13 were detected in more than 55% of HCCs. However, the DNA copy number gains of clones on 6p and 8q24.12 were more frequent in stage III/IV tumours than in stage I/II tumours (p < 0.001). In particular, the gain of the whole 6p was virtually limited to advanced-staged HCCs. The gain of the whole 6p is suggested to be a genomic marker for the late stages in HCCs. These observations therefore support the concept of genomic staging in HCC.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19097070     DOI: 10.1002/path.2491

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  22 in total

1.  Shank-interacting protein-like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells.

Authors:  Lizhi He; Alistair Ingram; Adrian P Rybak; Damu Tang
Journal:  J Clin Invest       Date:  2010-05-10       Impact factor: 14.808

Review 2.  Chemotherapy for advanced hepatocellular carcinoma in the sorafenib age.

Authors:  Koji Miyahara; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

Review 3.  Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?

Authors:  Yu-Yun Shao; Chih-Hung Hsu; Ann-Lii Cheng
Journal:  World J Gastroenterol       Date:  2015-09-28       Impact factor: 5.742

4.  EXO1 overexpression is associated with poor prognosis of hepatocellular carcinoma patients.

Authors:  Yaoyao Dai; Zuxiong Tang; Zongguo Yang; Lan Zhang; Qing Deng; Xiaofeng Zhang; Yongchun Yu; Xing Liu; Junfeng Zhu
Journal:  Cell Cycle       Date:  2018-10-20       Impact factor: 4.534

5.  A Panel of Genes Identified as Targets for 8q24.13-24.3 Gain Contributing to Unfavorable Overall Survival in Patients with Hepatocellular Carcinoma.

Authors:  Kun Zhao; Yu Zhao; Jia-Yi Zhu; Hui Dong; Wen-Ming Cong; Yi Yu; Hui Wang; Zhong-Zheng Zhu; Qing Xu
Journal:  Curr Med Sci       Date:  2018-08-20

6.  Cooperative antiproliferative effect of coordinated ectopic expression of DLC1 tumor suppressor protein and silencing of MYC oncogene expression in liver cancer cells: Therapeutic implications.

Authors:  Xuyu Yang; Xiaoling Zhou; Paul Tone; Marian E Durkin; Nicholas C Popescu
Journal:  Oncol Lett       Date:  2016-06-24       Impact factor: 2.967

7.  Aberrant upregulation of LRRC1 contributes to human hepatocellular carcinoma.

Authors:  Yandong Li; Bo Zhou; Jihong Dai; Ruifang Liu; Ze-Guang Han
Journal:  Mol Biol Rep       Date:  2013-05-06       Impact factor: 2.316

8.  Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.

Authors:  Katumi Tsuji; Shigeto Kawauchi; Soichiro Saito; Tomoko Furuya; Kenzo Ikemoto; Motonao Nakao; Shigeru Yamamoto; Masaaki Oka; Takashi Hirano; Kohsuke Sasaki
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

9.  Correlating genomic copy number alterations with clinicopathologic findings in 75 cases of hepatocellular carcinoma.

Authors:  Gang Peng; Hongyan Chai; Weizhen Ji; Yufei Lu; Shengming Wu; Hongyu Zhao; Peining Li; Qiping Hu
Journal:  BMC Med Genomics       Date:  2021-06-08       Impact factor: 3.063

10.  Development of biomarkers for screening hepatocellular carcinoma using global data mining and multiple reaction monitoring.

Authors:  Hyunsoo Kim; Kyunggon Kim; Su Jong Yu; Eun Sun Jang; Jiyoung Yu; Geunhee Cho; Jung-Hwan Yoon; Youngsoo Kim
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.